Stephen Whitehead is a seasoned executive leader in the biopharma/pharma sector with over 25 years experience in product strategy, development and commercialization. Stephen has spent the past four years as an independent consultant advising early/mid stage life-science companies. Currently he is President and COO at ScarX Therapeutics.
Prior to this Stephen was Vice President of Commercial & Strategic Advancement and a Management Committee Member at Wyeth (and Wyeth a Pfizer Company). He also held positions of increasing responsibility at American Cyanamid and J&J.
In addition, Stephen has an extensive background in business development, licensing and organizational development. Among his accomplishments, he established the first Biopharma Business Unit at Wyeth and went on to successfully lead the commercialization of two first in class biologics in Canada. Stephen holds a BSc (Hon) Biology degree from the University of Waterloo.